AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
AbbVie Inc. said Monday it will acquire Apogee Therapeutics, a clinical-stage biotechnology company, for $135.11 a share in cash, a deal valued at about $10.9 billion that deepens the drugmaker’s bet on immunology and gives it a late-stage treatment for eczema with a novel dosing advantage.
The price represents a premium of roughly 49% over Apogee’s closing share price on June 18, the last trading day before reports of a possible deal. The transaction, unanimously approved by both boards, is expected to close in the third quarter, subject to Apogee shareholder approval and regulatory clearance. AbbVie said it will fund the purchase with debt and expects the deal to trim adjusted earnings by about 14 cents a share this year and 46 cents next year, with accretion beginning in 2032.
The acquisition is AbbVie’s largest since it bought Botox maker Allergan for $63 billion in 2019, and one of the biggest biopharma deals of the year. It lands at a critical moment for the company: AbbVie’s immunology franchise, led by Skyrizi and Rinvoq, is still growing, but the patents on its earlier blockbusters have expired, and the company has been under pressure to show it can replace that revenue with new drugs.
What AbbVie is buying is a pipeline built around a single insight: patients would rather be injected twice a year than twice a month. Apogee’s lead asset, zumilokibart, is a half-life-extended antibody targeting IL-13, the signaling protein that drives the inflammation behind atopic dermatitis, the medical name for eczema. The company engineered the drug to remain active in the body for months, enabling dosing every three to six months, compared with the two-to-four-week intervals required by existing biologic treatments.
The company has described zumilokibart as a “pipeline in a product.” Beyond eczema, it is being studied in asthma and eosinophilic esophagitis, and Apogee has built combination programs around it: APG273, which pairs zumilokibart with an antibody that blocks TSLP, a trigger of airway inflammation, is in development for asthma and chronic obstructive pulmonary disease, and APG279, which combines it with an OX40L inhibitor, is in early trials for eczema.
The data so far are promising but early. Apogee completed the Part B portion of its Phase 2 trial in eczema with positive 16-week results, and the company was preparing to start Phase 3 testing in the second half of this year. A Phase 1 study comparing one of the combinations directly against Dupixent, the current standard of care, was fully enrolled as of mid-2026.
The eczema market is one of the largest and least penetrated in immunology. Dupixent, made by Regeneron and Sanofi, became a multibillion-dollar drug treating the condition, and a wave of new entrants has followed. What sets zumilokibart apart, analysts said, is the dosing: if patients can be treated with injections every few months rather than every few weeks, adherence improves and the drug’s addressable population expands to include milder patients who balk at frequent shots.
“This is a bet on dosing convenience as much as on efficacy,” one analyst said. “The science of IL-13 inhibition is established. The question is whether a six-month injection can expand the market the way once-a-day pills expanded other categories.”
For AbbVie, the deal also opens the respiratory market, where it has been underrepresented. The TSLP combination is aimed at severe asthma and COPD, areas where existing treatments leave many patients uncontrolled. AbbVie Chairman and Chief Executive Robert Michael said the acquisition “adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio in areas of significant patient need.”
The price is steep for a company with no approved products and no revenue. Apogee, which went public in 2023, had secured a $1.3 billion financing package from Blackstone Life Sciences just weeks before the deal was reported, suggesting it had the runway to develop zumilokibart independently. That AbbVie moved anyway, at a nearly 50% premium, reflects how competitive the market for late-stage immunology assets has become.
Apogee’s story shows how quickly biotech valuations can move. The company went public in 2023 at a time when investors were skeptical of me-too immunology assets, and its shares traded well below its offering price for much of its first year. Positive data from the Phase 2 trial changed that, and the acquisition price of $135.11 a share stands roughly eight times the level at which the stock traded a year ago. The deal is also a payday for the venture investors who funded the company, including Venrock and Fairmount, which have agreed to support the transaction.
Investors will now watch the Phase 3 program, which AbbVie takes over. Positive results would validate the premium; a setback would put the deal’s logic in doubt. The company’s largest shareholders, including Fairmount Funds Management and Venrock, have agreed to support the transaction.
For the broader industry, the deal is another sign that large drugmakers are willing to pay up for assets that can define a therapeutic category. AbbVie’s $10.9 billion bet says the company believes the next decade of immunology will be won with drugs that are easier to take, and that it is prepared to pay now for the chance to lead.
